Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VXM01 · 3 trials · 3 indications
AEs listed together with information on onset, duration, severity, seriousness, relationship to the study drug, relationship to chemotherapy and to the underlying disease, outcome, and action taken. Frequency tables by System Organ Class and preferred term.
Number of dose-limiting toxicities and maximum tolerated dose
| Arm | Type | Description |
|---|---|---|
| VXM01 | EXPERIMENTAL | VXM01 10E6 or 10E7 CFU |
| Placebo | PLACEBO_COMPARATOR | Placebo control |
| Name | Type | Description |
|---|---|---|
| VXM01 | DRUG | Oral immunotherapy targeting VEGFR2 |
| Placebo | BIOLOGICAL | Drink solution |
Inclusion Criteria: 1. Written informed consent, signed and dated 2. Histologically diagnosed intracranial supratentorial malignant glioma (contrast-enhancing anaplastic astrocytoma WHO Grade III or glioblastoma WHO Grade IV). 3. Male or female patients who must be post-menopausal for at least 2 ye...
Top 20 of 76 competitors
VXM01 is an investigational small molecule being studied for the treatment of Stage IV pancreatic cancer, colorectal cancer, and glioblastoma. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
VXM01 is being developed by OSR Holdings, Inc., a company publicly traded under the ticker symbol OSRH. The company is conducting clinical trials for this investigational oncology drug.
VXM01 is in Phase 1 clinical development. It is an investigational drug and has not received regulatory approval. All completed trials for VXM01 are Phase 1 studies.
VXM01 has been studied in three completed Phase 1 trials: NCT01486329 in Stage IV pancreatic cancer, NCT02718430 in metastatic colorectal cancer with liver metastasis, and NCT02718443 in operable recurrence of glioblastoma. These trials were conducted in Germany.
VXM01 is the primary name for this investigational drug. No alternative names have been reported for this asset in the available clinical trial information.